A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Azacitidine (Primary)
Indications Acute myeloid leukaemia; Autoimmune disorders; Chronic myelomonocytic leukaemia; Inflammation; Myelodysplastic syndromes
Focus Therapeutic Use

03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism
11 Oct 2021 Planned End Date changed from 1 Feb 2023 to 1 Oct 2022.
18 Jun 2020 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com